Horizon Pharma (HZNP) Tops Q2 EPS by 31c, Raises Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Horizon Pharma plc Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance
August 7, 2017 7:00 AM EDT-- Second-Quarter 2017 Net Sales of $289.5 Million; Up 12 Percent, Above Expectations ---- Second-Quarter 2017 Net Loss of $209.5 Million; Adjusted EBITDA of $127.0 Million, Above Expectations ---- Second-Quarter 2017 GAAP Operating Cash Flow of $47.9 Million; Non-GAAP Operating Cash Flow of $86.4 Million ---- Second-Quarter 2017 Net Sales of Rare Disease Medicines Increased 70 Percent ---- Completed Acquisition of River Vision Development Corp., Adding Late-Stage Development Biologic Teprotumumab ---- Completed Sale of EMEA Marketing Rights for PROCYSBI® and QUINSAIRTM ---- Increasing Full-Year 2017 Net Sales Guidance Range to $1.010 Billion to $1.045 Billion; Increasing Full-Year 2017 Adjusted EBITDA... More
